Reviewing Ionis Pharmaceuticals Inc. (IONS)’s and Dermira Inc. (NASDAQ:DERM)’s results

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Dermira Inc. (NASDAQ:DERM) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 599.67M 17.68 276.87M 0.51 137.95
Dermira Inc. 42.34M 7.59 221.54M -5.27 0.00

Table 1 highlights Ionis Pharmaceuticals Inc. and Dermira Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Ionis Pharmaceuticals Inc. and Dermira Inc.?s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. 46.17% -31.1% -8.7%
Dermira Inc. -523.24% -310.8% -50.7%

Volatility and Risk

Ionis Pharmaceuticals Inc.?s 2.39 beta indicates that its volatility is 139.00% more volatile than that of Standard and Poor’s 500. Competitively, Dermira Inc.’s beta is 1.34 which is 34.00% more volatile than Standard and Poor’s 500.

Liquidity

Ionis Pharmaceuticals Inc.?s Current Ratio is 8 while its Quick Ratio is 8. On the competitive side is, Dermira Inc. which has a 8.7 Current Ratio and a 8.5 Quick Ratio. Dermira Inc. is better positioned to pay off short and long-term obligations compared to Ionis Pharmaceuticals Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Ionis Pharmaceuticals Inc. and Dermira Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ionis Pharmaceuticals Inc. 0 0 1 3.00
Dermira Inc. 0 2 3 2.60

Ionis Pharmaceuticals Inc.?s upside potential is 7.04% at a $82 average target price. Competitively Dermira Inc. has an average target price of $15.75, with potential upside of 107.51%. The data provided earlier shows that Dermira Inc. appears more favorable than Ionis Pharmaceuticals Inc., based on analyst belief.

Insider & Institutional Ownership

Roughly 89.1% of Ionis Pharmaceuticals Inc. shares are owned by institutional investors while 90.3% of Dermira Inc. are owned by institutional investors. Insiders owned roughly 0.2% of Ionis Pharmaceuticals Inc.’s shares. Competitively, insiders own roughly 0.91% of Dermira Inc.?s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%
Dermira Inc. 18.46% 40% -18.01% -4.05% -61.94% 28.51%

For the past year Ionis Pharmaceuticals Inc.’s stock price has bigger growth than Dermira Inc.

Summary

Ionis Pharmaceuticals Inc. beats Dermira Inc. on 11 of the 13 factors.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.